Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PV1019 + Topotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PV1019 | CHK2 Inhibitor 7 | PV1019, a derivative of NSC109555, is an ATP-competitive inhibitor of CHK2, which leads to reduced CHK2 kinase activity and decreased tumor cell growth, and enhances the anti-tumor effects of chemotherapeutic agents (PMID: 19741151). | ||
Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|